Advanced search
Publication Cover
OncoImmunology Volume 12, 2023 - Issue 1
Submit an article Journal homepage
1,368
Views
4
CrossRef citations to date
0
Altmetric
Editorial

Arsenic trioxide as an inducer of immunogenic cell death

Oliver Keppa Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Université Paris Saclay, Villejuif, France, [email protected]ORCID Iconhttps://orcid.org/0000-0002-6081-9558
ORCID Icon,
Hui Panb Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France
,
Peng Liua Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Université Paris Saclay, Villejuif, France, [email protected];b Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France
&
Guido Kroemerc Institut du Cancer Paris CARPEM, Department of Biology, APHP, Hôpital Européen Georges Pompidou, Paris, FranceORCID Iconhttps://orcid.org/0000-0002-9334-4405
ORCID Icon
Article: 2174723 | Published online: 06 Feb 2023

References

  • Westervelt P, Pollock JL, Oldfather KM, Walter MJ, Ma MK, Williams A, DiPersio JF, Ley TJ. Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(14):9468–3. doi:10.1073/pnas.132657799.
  • de The H, Pandolfi PP, Chen Z. Acute promyelocytic Leukemia: a paradigm for oncoprotein-targeted cure. Cancer Cell. 2017;32(5):552–560. doi:10.1016/j.ccell.2017.10.002.
  • Deaglio S, Canella D, Baj G, Arnulfo A, Waxman S, Malavasi F. Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells. Leuk Res. 2001;25(3):227–235. doi:10.1016/S0145-2126(00)00105-3.
  • Mao MH, Huang HB, Zhang XL, Li K, Liu YL, Wang P. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway. Biomed Pharmacother. 2018;107:1093–1103. doi:10.1016/j.biopha.2018.08.057.
  • Thomas-Schoemann A, Batteux F, Mongaret C, Nicco C, Chereau C, Annereau M, Dauphin A, Goldwasser F, Weill B, Lemare F, et al. Arsenic trioxide exerts antitumor activity through regulatory T cell depletion mediated by oxidative stress in a murine model of colon cancer. J Immunol. 2012;189(11):5171–5177. doi:10.4049/jimmunol.1103094.
  • Chen J, Jin Z, Zhang S, Zhang X, Li P, Yang H, Ma Y. Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis. Cell Mol Immunol. 2022;20(1):51–64. doi:10.1038/s41423-022-00956-0.
  • Stoll G, Ma Y, Yang H, Kepp O, Zitvogel L, Kroemer G. Pro-necrotic molecules impact local immunosurveillance in human breast cancer. Oncoimmunology. 2017;6(4):e1299302. doi:10.1080/2162402X.2017.1299302.
  • Yang H, Ma Y, Chen G, Zhou H, Yamazaki T, Klein C, Pietrocola F, Vacchelli E, Souquere S, Sauvat A, et al. Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. Oncoimmunology. 2016;5(6):e1149673. doi:10.1080/2162402X.2016.1149673.
  • Lu Y, Xu F, Wang Y, Shi C, Sha Y, He G, Yao Q, Shao K, Sun W, Du J, et al. Cancer immunogenic cell death via photo-pyroptosis with light-sensitive Indoleamine 2,3-dioxygenase inhibitor conjugate. Biomaterials. 2021;278:121167. doi:10.1016/j.biomaterials.2021.121167.
  • Kepp O, Kroemer G. Is ferroptosis immunogenic? The devil is in the details! Oncoimmunology. 2022;11(1):2127273. doi:10.1080/2162402X.2022.2127273.
  • Tang D, Kepp O, Kroemer G. Ferroptosis becomes immunogenic: implications for anticancer treatments. Oncoimmunology. 2020;10(1):1862949. doi:10.1080/2162402X.2020.1862949.
  • Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23(4):487–500. doi:10.1038/s41590-022-01132-2.
  • Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860–875. doi:10.1038/nrc3380.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.